表纸
市场调查报告书
商品编码
996043

人体微生物组治疗药物市场报告(2021-2031):技术/治疗领域/类型/产品/地区和主要国家市场分析,主要企业和COVID-19回收方案

Human Microbiome Therapeutics Market Report 2021-2031: Forecasts by Technology, by Therapeutic Area, by Type, by Product, Regional & Leading National Market Analysis, Leading Companies, and COVID-19 Recovery Scenarios

出版日期: | 出版商: Visiongain Reports Ltd. | 英文 492 Pages | 商品交期: 最快1-2个工作天内

价格
  • 全貌
  • 简介
  • 目录
简介

本报告调查了全球人类微生物组治疗药物市场,除收益预测外,最近的业绩,增长率,市场份额和定性分析(市场动态,增长因素,机会,限制因素,问题),分析Covid19的影响以及主要公司的概况。

目录

第1章报告概述

第2章执行摘要

  • 要点

第3章人类微生物组治疗产品和技术概述

  • 人类微生物组治疗产品介绍
    • 人类微生物组
    • 肠道菌群
    • 口腔微生物群
    • 皮肤微生物组
  • 微生物组与人类健康和疾病
  • 人类微生物组的基本功能
  • 支持微生物群调查的技术
  • 耕种与栽培
    • 动物模型
    • 致生动物模型
    • 工程系统
    • 类器官培养
    • 生物反应器
    • 微生物群测定
    • 直接觀察
    • 数据分析
  • 微生物组治疗疾病领域
  • 微生物组治疗剂的调节状态
  • 微生物菌群调查项目

第4章微生物组治疗学的发展

  • 微生物群疗法
  • 活生物疗法产品(LBP)
  • 微生物群调节疗法
    • 小分子益生菌
    • 益生元
  • 减法微生物组治疗剂
  • 抗菌疗法
  • 噬菌体治疗

第5章市场动态

  • 概述
  • SWOT分析
  • 微生物组治疗药物市场的驱动力
    • 未满足的医疗需求很高
    • 进一步瞭解微生物组
    • 积极的投资环境
    • 强大的管道
    • 监管批准
  • 微生物组治疗市场的挑战
    • 缺乏监管指导
    • 产品表征和制造挑战
    • 临床前和临床研究中的障碍
    • 对熟练工人的需求
    • 新兴市场
    • 开发更好的诊断方法
    • 收购与伙伴关系
  • 对微生物组药物市场的威胁
    • 新的政府法规
    • 全球市场的激烈竞争
    • COVID-19大流行

第6章全球人类微生物组治疗药物市场

  • 全球市场概况
  • 全球市场前景(COVID-19影响恢复分析):货币基础
  • 按地区分列的全球市场前景(COVID-19影响恢复分析)
  • 全球技术前景
    • 人类微生物组治疗技术概述
    • 按技术分类的全球人类微生物组治疗药物市场(COVID-19之前的分析)
    • 按技术分类的全球人类微生物组治疗药物市场(COVID-19之后的效果恢复分析)
  • 治疗行业的全球市场前景(COVID-19影响恢复分析)
  • 按类型分列的全球市场前景
    • 粪便微生物群移植(FMT)
    • 活生物疗法产品(LBP)
    • 单克隆微生物
    • 人工细菌
    • 调节微生物组治疗
    • 减法微生物组治疗剂
    • 按类型划分的全球市场前景(COVID-19之前的分析)
    • 按类型划分的全球市场前景(COVID-19之后的影响恢复分析)
  • 按产品分列的全球市场展望(COVID-19影响恢复分析)

第7章北美人类微生物组治疗药物市场

  • 北美市场概述
  • 北美市场展望(COVID-19影响恢复分析):基于金额
  • 按国家划分的北美市场展望(COVID-19影响恢复分析)
  • 美国市场前景
    • 美国市场展望(COVID-19影响恢复分析):基于金额
  • 加拿大市场前景
    • 按价值划分的加拿大市场展望(COVID-19影响恢复分析)
  • 按技术分类的北美市场展望(COVID-19影响恢复分析)
  • 按治疗领域划分的北美市场展望(COVID-19影响恢复分析)
  • 按类型划分的北美市场前景(COVID-19影响恢复分析)
  • 按产品分列的北美市场前景(COVID-19影响恢复分析)

第8章欧洲人类微生物组治疗药物市场

  • 欧洲市场概述
  • 欧洲市场前景(COVID-19影响恢复分析):货币基础
  • 各国欧洲市场展望(COVID-19影响恢复分析)
  • 俄罗斯市场前景
    • 俄罗斯市场前景(COVID-19影响恢复分析):货币基础
  • 德国市场前景
  • 英国市场前景
  • 法国市场展望
  • 意大利市场前景
  • 其他欧洲市场前景
  • 按技术分类的欧洲市场前景(COVID-19影响恢复分析)
  • 按治疗领域划分的欧洲市场前景(COVID-19影响恢复分析)
  • 按类型划分的欧洲市场前景(COVID-19影响恢复分析)
  • 按产品分列的欧洲市场前景(COVID-19影响恢复分析)

第9章亚太人类微生物组治疗药物市场

  • 亚太市场概述
  • 亚太市场展望(COVID-19影响恢复分析):基于金额
  • 按国家/地区划分的亚太市场展望(COVID-19影响恢复分析)
  • 日本市场前景
    • 日本市场前景(COVID-19影响恢复分析):货币基础
  • 中国市场前景
  • 印度市场前景
  • 韩国市场前景
  • 澳大利亚市场前景
  • 其他亚太市场的剩余前景
  • 按技术分类的亚太市场展望(COVID-19影响恢复分析)
  • 按治疗领域划分的亚太市场展望(COVID-19影响恢复分析)
  • 按类型划分的亚太市场展望(COVID-19影响恢复分析)
  • 按产品分列的亚太市场展望(COVID-19影响恢复分析)

第10章LAMEA人体微生物组治疗药物市场

  • LAMEA市场概述
  • LAMEA市场前景(COVID-19影响恢复分析):货币基础
  • 按国家划分的LAMEA市场前景(COVID-19影响恢复分析)
  • 巴西市场前景
    • 巴西市场前景(COVID-19影响恢复分析):货币基础
  • 沙特阿拉伯市场前景
  • 南非市场前景
  • 墨西哥市场前景
  • 阿联酋市场前景
  • 其余LAMEA市场前景
  • 按技术分类的LAMEA市场前景(COVID-19影响恢复分析)
  • 按治疗领域划分的LAMEA市场前景(COVID-19影响恢复分析)
  • 按类型划分的LAMEA市场前景(COVID-19影响恢复分析)
  • 按产品分列的LAMEA市场前景(COVID-19影响恢复分析)

第11章竞争情况分析

  • 投资微生物组治疗
  • 公共筹资倡议
  • 私人融资计划
    • Sevencher合作伙伴
    • 旗舰先驱
  • 全球市场中的合作与伙伴关系
  • 许可和制造合同
  • 世界市场的并购
  • 微生物组治疗市场的主要市场参与者
  • Soga微生物组治疗药物市场的主要市场参与者
  • 调整后的微生物组治疗市场的主要市场参与者
  • 消减微生物组疗法市场的主要市场参与者

第12章世界人类微生物组专利分析

  • 专利概述
  • 专利分析
  • 年度专利
  • 专利类型
  • 按疾病类型划分的专利
  • 公司专有专利
  • 国家专利
  • 受让人的专利

第13章全球人类微生物组临床试验分析

  • 按疾病类别进行的临床试验分析
  • 临床试验份额
  • 通过治疗策略进行临床试验分析
  • 临床试验份额
  • 公司的临床试验分析
  • 临床试验份额
  • 发现和临床前开发中的微生物组疗法
  • 微生物组治疗的3期临床试验

第14章主要企业简介

  • AbbVie Inc.
  • Bristol-Myers Squibb
  • Dow Inc. Chemical
  • Takeda Pharmaceuticals Company Ltd.
  • Johnson & Johnson
  • DuPont de Nemours, Inc
  • Merck & Co. Inc
  • Pfizer Inc.
  • Vertex Pharmaceuticals
  • Evelo Biosciences, Inc
  • Kaleido Biosciences Inc
  • Seres Therapeutics Inc
  • PureTech Health PLC
  • Nestle S.A.
  • Mayo Clinic
  • MaaT Pharma SA
  • 4D Pharma Plc
  • Assembly Biosciences, Inc
  • F. Hoffmann-La Roche Ltd
  • Vedanta Biosciences

第15章结论和建议

第16章词汇表

目录
Product Code: PHA1025

Title:
Human Microbiome Therapeutics Market Report 2021-2031
Forecasts by Technology (Genomics, Proteomics, Metabolomics), by Therapeutic Area (Neurological Disorders, Dermatological Indications, Cancers, Metabolic Disorders, Gastrointestinal Disorders, Other Therapeutic Areas), by Type (Faecal Microbiota Transplantation (FMT), Microbiome Drugs, Microbiome Rebuilding, Microbiome Preserving), by Product (Probiotics & Prebiotics, Medical Food, Diagnostic Tests, Other Product) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Human Microbiome Therapeutics Companies AND COVID-19 Recovery Scenarios.

What is holding you back in the Human Microbiome Therapeutics Business?

Microbiome therapeutics have emerged as a novel therapeutic strategy, whereby living microbial cells or their components and metabolites are exploited to treat various diseases. Faecal microbial transplants (FMTs) have proved their success in treating recurring Clostridium difficile infections (CDI) for a long time. The potential of microbial therapeutics to address unmet medical needs has, therefore, been attracting many small- and big-players in this area. Still many human microbiome therapeutics companies are unable to make a move and grab this opportunity. In this report we have closely analysed human microbiome therapeutics market to find out a successful way out to grow in this tough crisis too. Buy our report to explore the goldmine areas in the global human microbiome therapeutics market.

Our 490+ page report provides 377 tables, 375 charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing human microbiome therapeutics market. Buy our report to see how to exploit these opportunities in the global market.

Forecasts to 2031 and other analyses reveal the commercial prospects

  • In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
  • You find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), Porter's Five Forces Analysis, product profiles and commercial developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.

Discover sales predictions for the global human microbiome therapeutics market and submarkets

Along with revenue prediction for the overall world market, there are 5 segmentations of the human microbiome therapeutics market, with forecasts for 3 technologies, 6 Therapeutic Area, 3 Types, 4 Products each forecasted at a global, regional, and country level, along with COVID-19 impact recovery pattern analysis for all segments.

Leading companies and the potential for market growth

As per Visiongain analysis, global human microbiome therapeutics market is estimated to be valued at US$xx million in 2020 and is projected to reach at a market value of US$xx million by 2031. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

What all Segments Are Covered in the Report?

Global Human Microbiome Therapeutics Market by Technology (COVID-19 Impact Recovery Analysis Covered)

  • Genomics
  • Proteomics
  • Metabolomics

Global Human Microbiome Therapeutics Market by Therapeutic Area (COVID-19 Impact Recovery Analysis Covered)

  • Neurological Disorders
  • Dermatological Indications
  • Cancers
  • Metabolic Disorders
  • Gastrointenstinal Disorders
  • Other Therapeutic Areas

Global Human Microbiome Therapeutics Market by Type (COVID-19 Impact Recovery Analysis Covered)

  • Fecal Microbiota Transplantation (FMT)
  • Microbiome Drugs
  • Microbiome Rebuilding
  • Microbiome Preserving

Global Human Microbiome Therapeutics Market by Product (COVID-19 Impact Recovery Analysis Covered)

  • Probiotics & Prebiotics
  • Medical Food
  • Diagnostic Tests
  • Other Product

Global Human Microbiome Therapeutics Market by Region (COVID-19 Impact Recovery Analysis Covered)

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East
  • Africa

Which Key Players Are Leading the Global Market and how much share do they Hold?

The global market for human microbiome therapeutics is ascending and has made significant gains in therapeutic treatments. The players in the human microbiome therapeutics market are striving to tap the opportunities that this market offers. Companies are trying to explore the available prospects by adopting various strategies such as:

  • Mergers and acquisitions.
  • Product launches.
  • Collaborations and partnerships.

Product approval is a major milestone facing all key competitors in the human microbiome therapeutics market. Several strategies were implemented by key market players between 2015 and Dec 2020. There are over 200 microbiome companies involved in different aspects of microbiome therapeutics, including drugs, diagnostics, biomarkers, services, analyses and others.

How the Human Microbiome Therapeutics Market report helps you? Buy this report to find answers for below questions and how can help you to stay updated

  • What is the current size of the overall global human human microbiome therapeutics market? How much will this market be worth from 2021 to 2031?
  • How will market shares of the leading national markets change by 2031, and which geographical region will lead the market in 2031?
  • Who are the leading companies and what are their activities, results, developments and prospects?
  • What are some of the most prominent human human microbiome therapeutics currently in development?
  • What are the main trends that will affect the world human microbiome therapeutics market between 2021 and 2031?
  • What are the main strengths, weaknesses, opportunities and threats for the market?
  • What are the social, technological, economic and political influences that will shape that industry over the next ten years?
  • How will the global human microbiome therapeutics market evolve over the forecasted period, 2021 to 2031?
  • How will the market shares for each checkpoint inhibitor anti-cancer treatment submarket develop from 2021 to 2031?
  • Which therapies can succeed and what revenues could they generate to 2031?
  • What will be the main commercial drivers for the market from 2021 to 2031?
  • How will market shares of prominent national markets change from 2021, and which countries will lead the market in 2031, achieving highest revenues and fastest growth?
  • How will that industry evolve between 2021 and 2031, especially in R&D?

Top 20 Leading Players Profiled in the Report:

  • AbbVie Inc. (AbbVie)
  • Bristol-Myers Squibb
  • Dow Inc Chemical
  • Takeda Pharmaceutical Company Limited
  • Johnson & Johnson
  • DuPont de Nemours, Inc.
  • Merck & Co. Inc
  • Pfizer Inc.
  • Vertex Pharmaceuticals
  • Evelo Biosciences, Inc.
  • Kaleido Biosciences, Inc.
  • Seres Therapeutics, Inc.
  • PureTech Health PLC
  • Nestle S.A.
  • Mayo Clinic
  • MaaT Pharma SA
  • 4D pharma plc (4D)
  • Assembly Biosciences, Inc
  • F. Hoffmann-La Roche Ltd
  • Vedanta Biosciences

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the precision cancer diagnostic tests Market and leading companies. You will find data, trends and predictions.

Buy our report today " Human Microbiome Therapeutics Market Report 2021-2031: Forecasts by Technology (Genomics, Proteomics, Metabolomics), by Therapeutic Area (Neurological Disorders, Dermatological Indications, Cancers, Metabolic Disorders, Gastrointestinal Disorders, Other Therapeutic Areas), by Type (Faecal Microbiota Transplantation (FMT), Microbiome Drugs, Microbiome Rebuilding, Microbiome Preserving), by Product (Probiotics & Prebiotics, Medical Food, Diagnostic Tests, Other Product) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Human Microbiome Therapeutics Companies AND COVID-19 Recovery Scenarios". Avoid missing out by staying informed - order our report now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1 Report Overview

  • 1.1 Global Human Microbiome Therapeutics Market Overview
  • 1.2 Study Goals and Objectives
  • 1.3 Why You Should Read This Report
  • 1.4 How This Report Delivers
  • 1.1 Key Questions Answered by This Analytical Report Include:
  • 1.2 Who is This Report For?
  • 1.3 Methodology
    • 1.4.1 Primary Research
    • 1.4.2 Secondary Research
    • 1.4.3 Data Sources
  • 1.4 Market Evaluation & Forecasting Methodology
  • 1.5 COIVD-19 Impact Recovery Pattern Analysis
    • 1.4.4 V-Shaped Recovery
    • 1.4.5 U-Shaped Recovery
    • 1.4.6 W-Shaped Recovery
    • 1.4.7 L-Shaped Recovery
  • 1.6 Frequently Asked Questions (FAQ)
  • 1.7 Associated Visiongain Reports
  • 1.8 About Visiongain

2 Executive Summary

  • 2.1 Key Take Away

3 Human Microbiome Therapeutics Products and Technology Overview

  • 3.1 Introduction to Human Microbiome Therapeutics Products
    • 3.1.1 The Human Microbiome
    • 3.1.2 Gut Microbiome
    • 3.1.3 Oral Microbiome
    • 3.1.4 Skin Microbiome
  • 3.2 Microbiome and Human Health and Disease
  • 3.3 Essential Functions of Human Microbiome
  • 3.4 Technologies Aiding Microbiome Research
  • 3.5 Culturing and Cultivation
    • 3.5.1 Animal Models
    • 3.5.2 Gnotobiotic Animal Models
    • 3.5.3 Engineered Systems
    • 3.5.4 Organoid Cultures
    • 3.5.5 Bioreactors
    • 3.5.6 Microbiome Assaying
    • 3.5.7 Direct Observation
    • 3.5.8 Data Analysis
  • 3.6 Microbiome Therapeutics Disease Areas
  • 3.7 Regulatory Landscape for Microbiome Therapeutics
  • 3.8 Microbiome Research Projects

4 Development of Microbiome Therapeutics

  • 4.1 Additive Microbiome Therapy
  • 4.2 Live Biotherapeutic Products (LBPs)
  • 4.3 Modulatory Microbiome Therapy
    • 4.3.1 Small Molecule Postbiotics
    • 4.3.2 Prebiotics
  • 4.4 Subtractive Microbiome Therapeutics
  • 4.5 Antimicrobial Therapy
  • 4.6 Phage Therapy

5 Market Dynamics

  • 5.1 Overview
  • 5.2 SWOT Analysis
  • 5.3 Drivers of Microbiome Therapeutics Market
    • 5.3.1 High Unmet Medical Need
    • 5.3.2 Growing Understanding of the Microbiome
    • 5.3.3 Positive Investment Environment
    • 5.3.4 Strong Pipeline
    • 5.3.5 Acceptance from Regulatory Authorities
  • 5.4 Challenges for Microbiome Therapeutics Market
    • 5.4.1 Lack of Regulatory Guidance
    • 5.4.2 Product Characterization and Manufacturing Challenges
    • 5.4.3 Hurdles in Preclinical and Clinical Research
    • 5.4.4 Need for Skilled Labor
    • 5.4.5 Emerging Markets
    • 5.4.6 Development of Better Diagnostic Methods
    • 5.4.7 Acquisitions and Partnerships
  • 5.5 Threats to the Microbiome Therapeutics Market
    • 5.5.1 New Government Regulations
    • 5.5.2 Stiff Competition in the Global Market
    • 5.5.3 COVID-19 Pandemic

6 Global Human Microbiome Therapeutics Market

  • 6.1 Global Market Overview
  • 6.2 Global Market Outlook in terms of Value (COVID-19 Impact Recovery Analysis)
  • 6.3 Global Market Outlook by Region (COVID-19 Impact Recovery Analysis)
  • 6.4 Global Market Outlook by Technology
    • 6.4.1 Human Microbiome Therapeutics Technology Overview
    • 6.4.2 Global Human Microbiome Therapeutics Market by Technology (Pre-COVID-19 Analysis)
    • 6.4.3 Global Human Microbiome Therapeutics Market by Technology (Post-COVID-19 Impact Recovery Analysis)
  • 6.5 Global Market Outlook by Therapeutics Areas (COVID-19 Impact Recovery Analysis)
  • 6.6 Global Market Outlook by Type
    • 6.6.1 Fecal Microbiota Transplants (FMTs)
    • 6.6.2 Live Biotherapeutic Products (LBPs)
    • 6.6.3 Monoclonal Microbials
    • 6.6.4 Engineered Bacteria
    • 6.6.5 Modulatory Microbiome Therapeutics
    • 6.6.6 Subtractive Microbiome Therapeutics
    • 6.6.7 Global Market Outlook by Type (Pre-COVID-19 Analysis)
    • 6.6.8 Global Market Outlook by Type (Post-COVID-19 Impact Recovery Analysis)
  • 6.7 Global Market Outlook by Product (COVID-19 Impact Recovery Analysis)

7 North America Human Microbiome Therapeutics Market

  • 7.1 North America Market Overview
  • 7.2 North America Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 7.3 North America Market Outlook by Country (COVID-19 Impact Recovery Analysis)
  • 7.4 US Market Outlook
    • 7.4.1 US Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 7.5 Canada Market Outlook
    • 7.5.1 Canada Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 7.6 North America Market Outlook by Technology (COVID-19 Impact Recovery Analysis)
  • 7.7 North America Market Outlook by Therapeutics Areas (COVID-19 Impact Recovery Analysis)
  • 7.8 North America Market Outlook by Type (COVID-19 Impact Recovery Analysis)
  • 7.9 North America Market Outlook by Product (COVID-19 Impact Recovery Analysis)

8 Europe Human Microbiome Therapeutics Market

  • 8.1 Europe Market Overview
  • 8.2 Europe Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 8.3 Europe Market Outlook by Country (COVID-19 Impact Recovery Analysis)
  • 8.4 Russia Market Outlook
    • 8.4.1 Russia Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 8.5 Germany Market Outlook
    • 8.5.1 Germany Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 8.6 UK Market Outlook
    • 8.6.1 UK Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 8.7 France Market Outlook
    • 8.7.1 France Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 8.8 Italy Market Outlook
    • 8.8.1 Italy Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 8.9 Rest of Europe Market Outlook
    • 8.9.1 Rest of Europe Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 8.10 Europe Market Outlook by Technology (COVID-19 Impact Recovery Analysis)
  • 8.11 Europe Market Outlook by Therapeutics Areas (COVID-19 Impact Recovery Analysis)
  • 8.12 Europe Market Outlook by Type (COVID-19 Impact Recovery Analysis)
  • 8.13 Europe Market Outlook by Product (COVID-19 Impact Recovery Analysis)

9 Asia-Pacific Human Microbiome Therapeutics Market

  • 9.1 Asia-Pacific Market Overview
  • 9.2 Asia-Pacific Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 9.3 Asia-Pacific Market Outlook by Country (COVID-19 Impact Recovery Analysis)
  • 9.4 Japan Market Outlook
    • 9.4.1 Japan Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 9.5 China Market Outlook
    • 9.5.1 China Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 9.6 India Market Outlook
    • 9.6.1 India Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 9.7 South Korea Market Outlook
    • 9.7.1 South Korea Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 9.8 Australia Market Outlook
    • 9.8.1 Australia Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 9.9 Rest of APAC Market Outlook
    • 9.9.1 Rest of APAC Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 9.10 Asia-Pacific Market Outlook by Technology (COVID-19 Impact Recovery Analysis)
  • 9.11 Asia-Pacific Market Outlook by Therapeutics Areas (COVID-19 Impact Recovery Analysis)
  • 9.12 Asia-Pacific Market Outlook by Type (COVID-19 Impact Recovery Analysis)
  • 9.13 Asia-Pacific Market Outlook by Product (COVID-19 Impact Recovery Analysis)

10 LAMEA Human Microbiome Therapeutics Market

  • 10.1 LAMEA Market Overview
  • 10.2 LAMEA Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 10.3 LAMEA Market Outlook by Country (COVID-19 Impact Recovery Analysis)
  • 10.4 Brazil Market Outlook
    • 10.4.1 Brazil Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 10.5 Saudi Arabia Market Outlook
    • 10.5.1 Saudi Arabia Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 10.6 South Africa Market Outlook
    • 10.6.1 South Africa Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 10.7 Mexico Market Outlook
    • 10.7.1 Mexico Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 10.8 UAE Market Outlook
    • 10.8.1 UAE Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 10.9 Rest od LAMEA Market Outlook
    • 10.9.1 Rest of LAMEA Market Outlook by Value (COVID-19 Impact Recovery Analysis)
  • 10.10 LAMEA Market Outlook by Technology (COVID-19 Impact Recovery Analysis)
  • 10.11 LAMEA Market Outlook by Therapeutics Areas (COVID-19 Impact Recovery Analysis)
  • 10.12 LAMEA Market Outlook by Type (COVID-19 Impact Recovery Analysis)
  • 10.13 LAMEA Market Outlook by Product (COVID-19 Impact Recovery Analysis)

11 Competitive Landscape Analysis

  • 11.1 Investment in Microbiome Therapeutics
  • 11.2 Public Funding Initiatives
  • 11.3 Private Funding Initiatives
    • 11.3.1 Seventure Partners
    • 11.3.2 Flagship Pioneering
  • 11.4 Collaborations and Partnerships in the Global Market
  • 11.5 Licensing and Manufacturing Agreements
  • 11.6 Mergers and Acquisitions in the Global Market
  • 11.7 Leading Market Players in Microbiome Therapeutics Market
  • 11.8 Leading Market Players in Additive Microbiome Therapeutics Market
  • 11.9 Leading Market Players in Modulatory Microbiome Therapeutics Market
  • 11.10 Leading Market Players in Subtractive Microbiome Therapeutics Market

12 Global Human Microbiome Patent Analysis

  • 12.1 Patent Overview
  • 12.2 Patent Analysis
  • 12.3 Patents by Year
  • 12.4 Patents by Type
  • 12.5 Patents by Disease Type
  • 12.6 Patents by Company
  • 12.7 Patents by Country
  • 12.8 Patents by Assignee

13 Global Human Microbiome Clinical Trial Analysis

  • 13.1 Clinical Trial Analysis by Disease Category
  • 13.2 Share of Clinical Trials
  • 13.3 Clinical Trial Analysis by Treatment Strategy
  • 13.4 Share of Clinical Trials
  • 13.5 Clinical Trial Analysis by Company
  • 13.6 Share of Clinical Trials
  • 13.7 Microbiome Therapeutics in Discovery and Preclinical Development
  • 13.8 Microbiome Therapeutics Clinical Trials in Phase 3

14 Leading Company Profiles

  • 14.1 AbbVie Inc. Company
    • 14.1.1 Company Information
    • 14.1.2 Company Overview
    • 14.1.3 Company Financial Profile
    • 14.1.4 Company Product Offerings
    • 14.1.5 Company Recent Developments
  • 14.2 Bristol-Myers Squibb Company
    • 14.2.1 Company Information
    • 14.2.2 Company Overview
    • 14.2.3 Company Financial Profile
    • 14.2.4 Company Product Offerings
    • 14.2.5 Company Recent Developments
  • 14.3 Dow Inc. Chemical Company
    • 14.3.1 Company Information
    • 14.3.2 Company Overview
    • 14.3.3 Company Financial Profile
    • 14.3.4 Company Product Offerings
    • 14.3.5 Company Recent Developments
  • 14.4 Takeda Pharmaceuticals Company Ltd.
    • 14.4.1 Company Information
    • 14.4.2 Company Overview
    • 14.4.3 Company Financial Profile
    • 14.4.4 Company Product Offerings
    • 14.4.5 Company Recent Developments
  • 14.5 Johnson & Johnson Company
    • 14.5.1 Company Information
    • 14.5.2 Company Overview
    • 14.5.3 Company Financial Profile
    • 14.5.4 Company Product Offerings
    • 14.5.5 Company Recent Developments
  • 14.6 DuPont de Nemours, Inc Company
    • 14.6.1 Company Information
    • 14.6.2 Company Overview
    • 14.6.3 Company Financial Profile
    • 14.6.4 Company Product Offerings
    • 14.6.5 Company Recent Developments
  • 14.7 Merck & Co. Inc Company
    • 14.7.1 Company Information
    • 14.7.2 Company Overview
    • 14.7.3 Company Financial Profile
    • 14.7.4 Company Product Offerings
    • 14.7.5 Company Recent Developments
  • 14.8 Pfizer Inc. Company
    • 14.8.1 Company Information
    • 14.8.2 Company Overview
    • 14.8.3 Company Financial Profile
    • 14.8.4 Company Product Offerings
    • 14.8.5 Company Recent Developments
  • 14.9 Vertex Pharmaceuticals Company
    • 14.9.1 Company Information
    • 14.9.2 Company Overview
    • 14.9.3 Company Financial Profile
    • 14.9.4 Company Product Offerings
    • 14.9.5 Company Recent Developments
  • 14.10 Evelo Biosciences, Inc Company
    • 14.10.1 Company Information
    • 14.10.2 Company Overview
    • 14.10.3 Company Financial Profile
    • 14.10.4 Company Product Offerings
    • 14.10.5 Company Recent Developments
  • 14.11 Kaleido Biosciences Inc Company
    • 14.11.1 Company Information
    • 14.11.2 Company Overview
    • 14.11.3 Company Financial Profile
    • 14.11.4 Company Product Offerings
    • 14.11.5 Company Recent Developments
  • 14.12 Seres Therapeutics Inc Company
    • 14.12.1 Company Information
    • 14.12.2 Company Overview
    • 14.12.3 Company Financial Profile
    • 14.12.4 Company Product Offerings
    • 14.12.5 Company Recent Developments
  • 14.13 PureTech Health PLC Company
    • 14.13.1 Company Information
    • 14.13.2 Company Overview
    • 14.13.3 Company Financial Profile
    • 14.13.4 Company Product Offerings
    • 14.13.5 Company Recent Developments
  • 14.14 Nestle S.A. Company
    • 14.14.1 Company Information
    • 14.14.2 Company Overview
    • 14.14.3 Company Financial Profile
    • 14.14.4 Company Product Offerings
    • 14.14.5 Company Recent Developments
  • 14.15 Mayo Clinic Company
    • 14.15.1 Company Information
    • 14.15.2 Company Overview
    • 14.15.3 Company Financial Profile
    • 14.15.4 Company Product Offerings
    • 14.15.5 Company Recent Developments
  • 14.16 MaaT Pharma SA Company
    • 14.16.1 Company Information
    • 14.16.2 Company Overview
    • 14.16.3 Company Financial Profile
    • 14.16.4 Company Product Offerings
    • 14.16.5 Company Recent Developments
  • 14.17 4D Pharma Plc Company
    • 14.17.1 Company Information
    • 14.17.2 Company Overview
    • 14.17.3 Company Financial Profile
    • 14.17.4 Company Product Offerings
    • 14.17.5 Company Recent Developments
  • 14.18 Assembly Biosciences, Inc Company
    • 14.18.1 Company Information
    • 14.18.2 Company Overview
    • 14.18.3 Company Financial Profile
    • 14.18.4 Company Product Offerings
    • 14.18.5 Company Recent Developments
  • 14.19 F. Hoffmann-La Roche Ltd Company
    • 14.19.1 Company Information
    • 14.19.2 Company Overview
    • 14.19.3 Company Financial Profile
    • 14.19.4 Company Product Offerings
    • 14.19.5 Company Recent Developments
  • 14.20 Vedanta Biosciences Company
    • 14.20.1 Company Information
    • 14.20.2 Company Overview
    • 14.20.3 Company Financial Profile
    • 14.20.4 Company Product Offerings
    • 14.20.5 Company Recent Developments

15 Conclusion & Recommendations

16 Glossary

List of Figures

  • Figure 1.1 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %)
  • Figure 3.1 Differences in Human Genome and Microbiome
  • Figure 3.2 Bacterial Distribution, by Body Site
  • Figure 3.3 Essential Functions of Human Microbiome
  • Figure 5.1 SWOT Analysis of Global Human Microbiome Therapeutics Market
  • Figure 6.1 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %)
  • Figure 6.2 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 6.3 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 6.4 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 6.5 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 6.6 Global Human Microbiome Therapeutics Market by Region Forecast 2021-2031 (US$ million, AGR %)
  • Figure 6.7 Global Human Microbiome Therapeutics Market by Region Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 6.8 Global Human Microbiome Therapeutics Market by Region Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 6.9 Global Human Microbiome Therapeutics Market by Region Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 6.10 Global Human Microbiome Therapeutics Market by Region Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 6.11 Global Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %)
  • Figure 6.12 Global Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 6.13 Global Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 6.14 Global Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 6.15 Global Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 6.16 Global Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %)
  • Figure 6.17 Global Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 6.18 Global Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 6.19 Global Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 6.20 Global Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 6.21 Global Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %)
  • Figure 6.22 Global Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 6.23 Global Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 6.24 Global Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 6.25 Global Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 6.26 Global Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %)
  • Figure 6.27 Global Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 6.28 Global Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 6.29 Global Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 6.30 Global Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 7.1 North America Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %)
  • Figure 7.2 North America Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 7.3 North America Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 7.4 North America Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 7.5 North America Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 7.6 North America Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %)
  • Figure 7.7 North America Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 7.8 North America Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 7.9 North America Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 7.10 North America Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 7.11 North America Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %)
  • Figure 7.12 North America Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 7.13 North America Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 7.14 North America Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 7.15 North America Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 7.16 North America Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %)
  • Figure 7.17 North America Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 7.18 North America Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 7.19 North America Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 7.20 North America Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 7.21 North America Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %)
  • Figure 7.22 North America Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 7.23 North America Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 7.24 North America Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 7.25 North America Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 7.26 North America Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %)
  • Figure 7.27 North America Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 7.28 North America Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 7.29 North America Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 7.30 North America Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 8.1 Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %)
  • Figure 8.2 Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 8.3 Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 8.4 Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 8.5 Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 8.6 Europe Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %)
  • Figure 8.7 Europe Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 8.8 Europe Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 8.9 Europe Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 8.10 Europe Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 8.11 Europe Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %)
  • Figure 8.12 Europe Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 8.13 Europe Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 8.14 Europe Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 8.15 Europe Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 8.16 Europe Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %)
  • Figure 8.17 Europe Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 8.18 Europe Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 8.19 Europe Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 8.20 Europe Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 8.21 Europe Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %)
  • Figure 8.22 Europe Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 8.23 Europe Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 8.24 Europe Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 8.25 Europe Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 8.26 Europe Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %)
  • Figure 8.27 Europe Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 8.28 Europe Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 8.29 Europe Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 8.30 Europe Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 9.1 Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %)
  • Figure 9.2 Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 9.3 Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 9.4 Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 9.5 Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 9.6 Asia-Pacific Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %)
  • Figure 9.7 Asia-Pacific Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 9.8 Asia-Pacific Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 9.9 Asia-Pacific Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 9.10 Asia-Pacific Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 9.11 Asia-Pacific Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %)
  • Figure 9.12 Asia-Pacific Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 9.13 Asia-Pacific Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 9.14 Asia-Pacific Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 9.15 Asia-Pacific Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 9.16 Asia-Pacific Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %)
  • Figure 9.17 Asia-Pacific Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 9.18 Asia-Pacific Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 9.19 Asia-Pacific Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 9.20 Asia-Pacific Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 9.21 Asia-Pacific Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %)
  • Figure 9.22 Asia-Pacific Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 9.23 Asia-Pacific Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 9.24 Asia-Pacific Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 9.25 Asia-Pacific Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 9.26 Asia-Pacific Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %)
  • Figure 9.27 Asia-Pacific Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 9.28 Asia-Pacific Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 9.29 Asia-Pacific Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 9.30 Asia-Pacific Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 10.1 LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %)
  • Figure 10.2 LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 10.3 LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 10.4 LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 10.5 LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 10.6 LAMEA Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %)
  • Figure 10.7 LAMEA Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 10.8 LAMEA Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 10.9 LAMEA Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 10.10 LAMEA Human Microbiome Therapeutics Market by Country Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 10.11 LAMEA Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %)
  • Figure 10.12 LAMEA Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 10.13 LAMEA Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 10.14 LAMEA Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 10.15 LAMEA Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 10.16 LAMEA Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %)
  • Figure 10.17 LAMEA Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 10.18 LAMEA Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 10.19 LAMEA Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 10.20 LAMEA Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 10.21 LAMEA Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %)
  • Figure 10.22 LAMEA Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 10.23 LAMEA Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 10.24 LAMEA Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 10.25 LAMEA Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 10.26 LAMEA Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %)
  • Figure 10.27 LAMEA Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (V-Shaped recovery)
  • Figure 10.28 LAMEA Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (W-Shaped recovery)
  • Figure 10.29 LAMEA Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (U-Shaped recovery)
  • Figure 10.30 LAMEA Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %) (L-Shaped recovery)
  • Figure 14.1 AbbVie Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 14.2 AbbVie Inc: Company Operating Income 2015-2019 (US$Mn)
  • Figure 14.3 AbbVie Inc: Company EBITDA 2015-2019 (US$Mn)
  • Figure 14.4 AbbVie Inc: Company Net Income/Loss 2015-2019 (US$Mn)
  • Figure 14.5 Bristol-Myers Squibb: Company Revenue 2015-2019 (US $Mn, AGR %)
  • Figure 14.6 Bristol-Myers Squibb: Company Operating Income 2015-2019 (US $Mn)
  • Figure 14.7 Bristol-Myers Squibb: Company EBITDA 2015-2019 (US $Mn)
  • Figure 14.8 Bristol-Myers Squibb: Company Net Income/Loss 2015-2019 (US $Mn)
  • Figure 14.9 Dow Inc Chemical: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 14.10 Dow Inc Chemical: Company Operating Income 2015-2019 (US$Mn)
  • Figure 14.11 Dow Inc Chemical: Company EBITDA 2015-2019 (US$Mn)
  • Figure 14.12 Dow Inc Chemical: Company Net Income/Loss 2015-2019 (US$Mn)
  • Figure 14.13 Takeda Pharmaceuticals: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 14.14 Takeda Pharmaceuticals: Company Operating Income 2015-2019 (US$Mn)
  • Figure 14.15 Takeda Pharmaceuticals: Company EBITDA 2015-2019 (US$Mn)
  • Figure 14.16 Takeda Pharmaceuticals: Company Net Income/Loss 2015-2019 (US$Mn)
  • Figure 14.17 Johnson & Johnson: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 14.18 Johnson & Johnson: Company Operating Income 2015-2019 (US$Mn)
  • Figure 14.19 Johnson & Johnson: Company EBITDA 2015-2019 (US$Mn)
  • Figure 14.20 Johnson & Johnson: Company Net Income/Loss 2015-2019 (US$Mn)
  • Figure 14.21 KKK: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 14.22 KKK: Company Operating Income 2015-2019 (US$Mn)
  • Figure 14.23 KKK: Company EBITDA 2015-2019 (US$Mn)
  • Figure 14.24 KKK: Company Net Income/Loss 2015-2019 (US$Mn)
  • Figure 14.25 Merck & Co. Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 14.26 Merck & Co. Inc: Company Operating Income 2015-2019 (US$Mn)
  • Figure 14.27 Merck & Co. Inc: Company EBITDA 2015-2019 (US$Mn)
  • Figure 14.28 Merck & Co. Inc: Company Net Income/Loss 2015-2019 (US$Mn)
  • Figure 14.29 Pfizer Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 14.30 Pfizer Inc: Company Operating Income 2015-2019 (US$Mn)
  • Figure 14.31 Pfizer Inc: Company EBITDA 2015-2019 (US$Mn)
  • Figure 14.32 Pfizer Inc: Company Net Income/Loss 2015-2019 (US$Mn)
  • Figure 14.33 Vertex Pharmaceuticals: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 14.34 Vertex Pharmaceuticals: Company Operating Income 2015-2019 (US$Mn)
  • Figure 14.35 Vertex Pharmaceuticals: Company EBITDA 2015-2019 (US$Mn)
  • Figure 14.36 Vertex Pharmaceuticals: Company Net Income/Loss 2015-2019 (US$Mn)
  • Figure 14.37 Evelo Biosciences, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 14.38 Evelo Biosciences, Inc: Company Operating Income 2015-2019 (US$Mn)
  • Figure 14.39 Evelo Biosciences, Inc: Company EBITDA 2015-2019 (US$Mn)
  • Figure 14.40 Evelo Biosciences, Inc: Company Net Income/Loss 2015-2019 (US$Mn)
  • Figure 14.41 Kaleido Biosciences, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 14.42 Kaleido Biosciences, Inc: Company Operating Income 2015-2019 (US$Mn)
  • Figure 14.43 Kaleido Biosciences, Inc: Company EBITDA 2015-2019 (US$Mn)
  • Figure 14.44 Kaleido Biosciences, Inc: Company Net Income/Loss 2015-2019 (US$Mn)
  • Figure 14.45 Seres Therapeutics, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 14.46 Seres Therapeutics, Inc: Company Operating Income 2015-2019 (US$Mn)
  • Figure 14.47 Seres Therapeutics, Inc: Company EBITDA 2015-2019 (US$Mn)
  • Figure 14.48 Seres Therapeutics, Inc: Company Net Income/Loss 2015-2019 (US$Mn)
  • Figure 14.49 PureTech Health Plc: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 14.50 PureTech Health Plc: Company Operating Income 2015-2019 (US$Mn)
  • Figure 14.51 PureTech Health Plc: Company EBITDA 2015-2019 (US$Mn)
  • Figure 14.52 PureTech Health Plc: Company Net Income/Loss 2015-2019 (US$Mn)
  • Figure 14.53 Nestle S.A.: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 14.54 Nestle S.A.: Company Operating Income 2015-2019 (US$Mn)
  • Figure 14.55 Nestle S.A.: Company EBITDA 2015-2019 (US$Mn)
  • Figure 14.56 Nestle S.A.: Company Net Income/Loss 2015-2019 (US$Mn)
  • Figure 14.57 4D Pharma Plc: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 14.58 4D Pharma Plc: Company Operating Income 2015-2019 (US$Mn)
  • Figure 14.59 4D Pharma Plc: Company EBITDA 2015-2019 (US$Mn)
  • Figure 14.60 4D Pharma Plc: Company Net Income/Loss 2015-2019 (US$Mn)
  • Figure 14.61 Assembly Biosciences, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 14.62 Assembly Biosciences, Inc: Company Operating Income 2015-2019 (US$Mn)
  • Figure 14.63 Assembly Biosciences, Inc: Company EBITDA 2015-2019 (US$Mn)
  • Figure 14.64 Assembly Biosciences, Inc: Company Net Income/Loss 2015-2019 (US$Mn)
  • Figure 14.65 F. Hoffmann-La Roche Ltd: Company Revenue 2015-2019 (US $Mn, AGR %)
  • Figure 14.66 F. Hoffmann-La Roche Ltd: Company Operating Income 2015-2019 (US $Mn)
  • Figure 14.67 F. Hoffmann-La Roche Ltd: Company EBITDA 2015-2019 (US $Mn)
  • Figure 14.68 F. Hoffmann-La Roche Ltd: Company Net Income/Loss 2015-2019 (US $Mn)

List of Tables

  • Table 1.1 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 2.1 Global Human Microbiome Therapeutics Market Summary Table
  • Table 3.1 Technologies for Microbiome Research
  • Table 3.2 Dysbiosis in Microbiome
  • Table 6.1 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 6.2 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 6.3 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 6.4 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 6.5 Global Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 6.6 Global Human Microbiome Therapeutics Market by Region Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 6.7 Global Human Microbiome Therapeutics Market by Region Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 6.8 Global Human Microbiome Therapeutics Market by Region Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 6.9 Global Human Microbiome Therapeutics Market by Region Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 6.10 Global Human Microbiome Therapeutics Market by Region Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 6.11 Global Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 6.12 Global Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 6.13 Global Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 6.14 Global Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 6.15 Global Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 6.16 Global Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 6.17 Global Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 6.18 Global Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 6.19 Global Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 6.20 Global Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 6.21 Modulatory Microbiome Therapeutics
  • Table 6.22 Global Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 6.23 Global Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 6.24 Global Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 6.25 Global Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 6.26 Global Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 6.27 Global Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 6.28 Global Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 6.29 Global Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 6.30 Global Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 6.31 Global Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 7.1 North America Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 7.2 North America Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 7.3 North America Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 7.4 North America Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 7.5 North America Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 7.6 US Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 7.7 US Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 7.8 US Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 7.9 US Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 7.10 US Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 7.11 Canada Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 7.12 Canada Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 7.13 Canada Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 7.14 Canada Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 7.15 Canada Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 7.16 North America Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 7.17 North America Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 7.18 North America Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 7.19 North America Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 7.20 North America Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 7.21 North America Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 7.22 North America Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 7.23 North America Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 7.24 North America Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 7.25 North America Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 7.26 North America Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 7.27 North America Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 7.28 North America Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 7.29 North America Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 7.30 North America Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 7.31 North America Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 7.32 North America Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 7.33 North America Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 7.34 North America Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 7.35 North America Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 8.1 Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 8.2 Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 8.3 Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 8.4 Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 8.5 Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 8.6 Russia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 8.7 Russia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 8.8 Russia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 8.9 Russia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 8.10 Russia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 8.11 Germany Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 8.12 Germany Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 8.13 Germany Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 8.14 Germany Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 8.15 Germany Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 8.16 UK Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 8.17 UK Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 8.18 UK Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 8.19 UK Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 8.20 UK Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 8.21 France Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 8.22 France Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 8.23 France Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 8.24 France Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 8.25 France Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 8.26 Italy Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 8.27 Italy Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 8.28 Italy Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 8.29 Italy Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 8.30 Italy Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 8.31 Rest of Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 8.32 Rest of Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 8.33 Rest of Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 8.34 Rest of Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 8.35 Rest of Europe Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 8.36 Europe Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 8.37 Europe Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 8.38 Europe Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 8.39 Europe Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 8.40 Europe Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 8.41 Europe Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 8.42 Europe Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 8.43 Europe Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 8.44 Europe Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 8.45 Europe Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 8.46 Europe Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 8.47 Europe Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 8.48 Europe Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 8.49 Europe Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 8.50 Europe Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 8.51 Europe Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 8.52 Europe Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 8.53 Europe Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 8.54 Europe Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 8.55 Europe Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 9.1 Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 9.2 Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 9.3 Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 9.4 Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 9.5 Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 9.6 Japan Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 9.7 Japan Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 9.8 Japan Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 9.9 Japan Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 9.10 Japan Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 9.11 China Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 9.12 China Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 9.13 China Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 9.14 China Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 9.15 China Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 9.16 India Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 9.17 India Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 9.18 India Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 9.19 India Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 9.20 India Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 9.21 South Korea Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 9.22 South Korea Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 9.23 South Korea Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 9.24 South Korea Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 9.25 South Korea Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 9.26 Australia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 9.27 Australia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 9.28 Australia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 9.29 Australia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 9.30 Australia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 9.31 Rest of Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 9.32 Rest of Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 9.33 Rest of Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 9.34 Rest of Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 9.35 Rest of Asia-Pacific Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 9.36 Asia-Pacific Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 9.37 Asia-Pacific Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 9.38 Asia-Pacific Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 9.39 Asia-Pacific Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 9.40 Asia-Pacific Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 9.41 Asia-Pacific Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 9.42 Asia-Pacific Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 9.43 Asia-Pacific Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 9.44 Asia-Pacific Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 9.45 Asia-Pacific Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 9.46 Asia-Pacific Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 9.47 Asia-Pacific Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 9.48 Asia-Pacific Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 9.49 Asia-Pacific Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 9.50 Asia-Pacific Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 9.51 Asia-Pacific Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 9.52 Asia-Pacific Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 9.53 Asia-Pacific Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 9.54 Asia-Pacific Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 9.55 Asia-Pacific Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 10.1 LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 10.2 LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 10.3 LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 10.4 LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 10.5 LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 10.6 Brazil Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 10.7 Brazil Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 10.8 Brazil Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 10.9 Brazil Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 10.10 Brazil Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 10.11 Saudi Arabia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 10.12 Saudi Arabia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 10.13 Saudi Arabia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 10.14 Saudi Arabia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 10.15 Saudi Arabia Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 10.16 South Africa Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 10.17 South Africa Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 10.18 South Africa Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 10.19 South Africa Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 10.20 South Africa Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 10.21 Mexico Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 10.22 Mexico Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 10.23 Mexico Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 10.24 Mexico Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 10.25 Mexico Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 10.26 UAE Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 10.27 UAE Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 10.28 UAE Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 10.29 UAE Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 10.30 UAE Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 10.31 Rest of LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 10.32 Rest of LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 10.33 Rest of LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 10.34 Rest of LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 10.35 Rest of LAMEA Human Microbiome Therapeutics Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 10.36 LAMEA Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 10.37 LAMEA Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 10.38 LAMEA Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 10.39 LAMEA Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 10.40 LAMEA Human Microbiome Therapeutics Market by Technology Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 10.41 LAMEA Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 10.42 LAMEA Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 10.43 LAMEA Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 10.44 LAMEA Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 10.45 LAMEA Human Microbiome Therapeutics Market by Therapeutic Area Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 10.46 LAMEA Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 10.47 LAMEA Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 10.48 LAMEA Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 10.49 LAMEA Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 10.50 LAMEA Human Microbiome Therapeutics Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 10.51 LAMEA Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %)
  • Table 10.52 LAMEA Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (V-Shaped recovery)
  • Table 10.53 LAMEA Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (W-Shaped recovery)
  • Table 10.54 LAMEA Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (U-Shaped recovery)
  • Table 10.55 LAMEA Human Microbiome Therapeutics Market by Product Forecast 2021-2031 (US$ million, AGR %, CAGR %) (L-Shaped recovery)
  • Table 11.1 Historical Funding Activity in Microbiome Therapeutics, 2015 and 2016
  • Table 11.2 Public Funding in Microbiome Therapeutics, 2018-August 2020
  • Table 11.3 Venture Funding in Microbiome Therapeutics, 2017-August 2020
  • Table 11.4 Collaborations and Partnerships in the Microbiome Therapeutics Market, 2017-August 2020
  • Table 11.5 Licensing and Manufacturing Agreements in the Microbiome Therapeutics Market, 2017-August 2020
  • Table 11.6 Leading Developers of Additive Microbiome Therapeutics, 2019
  • Table 11.7 Leading Developers of Modulatory Microbiome Therapeutics, 2019
  • Table 11.8 Leading Developers of Subtractive Microbiome Therapeutics, 2019
  • Table 12.1 Patents Issued for Microbiome Therapeutics, by Year, 2017-August 2020 (Number)
  • Table 12.2 Patents Issued for Microbiome Therapeutics, by Type, 2017- August 2020 (Number/%)
  • Table 12.3 Patents Issued for Microbiome Therapeutics, by Disease Type, 2017-August 2020 (Number/%)
  • Table 12.4 Patents Issued for Microbiome Therapeutics, by Company, 2017-August 2020 (Number)
  • Table 12.5 Patents Issued for Microbiome Therapeutics, by Country, 2017-August 2020 (Number/%)
  • Table 12.6 Patents Issued for Microbiome Therapeutics, by Assignee, 2017-August 2020 (Number/%)
  • Table 13.1 Clinical Trials in Microbiome Therapeutics, by Disease Type, August 2020 (Number)
  • Table 13.2 Share of Clinical Trials in Microbiome Therapeutics, by Disease Type, August 2020 (%)
  • Table 13.3 Clinical Trials in Microbiome Therapeutics, by Treatment Strategy
  • Table 13.4 Share of Clinical Trials in Microbiome Therapeutics, by Treatment Strategy (%)
  • Table 13.5 Clinical Trials in Microbiome Therapeutics, by Company
  • Table 13.6 Share of Clinical Trials in Microbiome Therapeutics, by Top 10 Companies (%)
  • Table 13.7 Microbiome Therapeutics in Discovery and Preclinical Development
  • Table 13.8 Microbiome Therapeutics Clinical Trials in Phase 3
  • Table 14.1 AbbVie Inc: Company Information
  • Table 14.2 AbbVie Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Table 14.3 AbbVie Inc: Company Product and Service Offerings
  • Table 14.4 AbbVie Inc: Company Product Pipeline
  • Table 14.5 AbbVie Inc: Company Recent Developments till Sept,2020
  • Table 14.6 Bristol-Myers Squibb: Company Information
  • Table 14.7 Bristol-Myers Squibb: Company Revenue 2015-2019 (US $Mn, AGR %)
  • Table 14.8 Bristol-Myers Squibb: Company Product and Service Offerings
  • Table 14.9 Bristol-Myers Squibb: Company Product Pipeline
  • Table 14.17 Takeda Pharmaceuticals: Company Product and Service Offerings

List of Companies Profiled:

  • 4D pharma plc (4D)
  • AbbVie Inc. (AbbVie)
  • Assembly Biosciences, Inc
  • Bristol-Myers Squibb
  • Dow Inc Chemical
  • DuPont de Nemours, Inc.
  • Evelo Biosciences, Inc.
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Kaleido Biosciences, Inc.
  • MaaT Pharma SA
  • Mayo Clinic
  • Merck & Co. Inc
  • Nestle S.A.
  • Pfizer Inc.
  • PureTech Health PLC
  • Seres Therapeutics, Inc.
  • Takeda Pharmaceutical Company Limited
  • Vedanta Biosciences
  • Vertex Pharmaceuticals

List of Other Companies:

  • Accinov
  • ActoGeniX
  • Aju IB Investment
  • Ally Bridge Group
  • Amrita Therapeutics
  • AOBiome, LLC
  • AquaBounty Technologies
  • Arctic Aurora Life Science
  • Assembly Biosciences
  • Azitra
  • BaseClear
  • Bio-Technology General
  • BIOASTER
  • Biological & Popular Culture, Inc.
  • BiomX
  • Bioverativ Therapeutics
  • Blue Turtle Bio
  • Bristol-Myers Squibb
  • BYTC Corp
  • C3J Therapeutics
  • Caelus Health
  • Cd4 Biosciences, Inc.
  • Cedars-Sinai Medical Centre
  • Chengdu Sen Nuo Wei Biotechnology Co., Ltd
  • CLI Ventures
  • Codexis Laboratories Hungary Kft
  • CoreBiome
  • Crestovo
  • CRS Bio, Inc
  • DayTwo
  • Effective Pharmaceuticals, Inc.
  • Enterome Bioscience
  • Enterome SA
  • EnviroFlight, LLC
  • Epibiome
  • Epitope Pharmaceuticals, Inc.
  • Evelo Biosciences
  • Evolve BioSystems
  • Ferring Pharmaceuticals
  • Ferring Sas
  • Finch Therapeutics
  • Finch Therapeutics Group, Inc.
  • Genomatix Ltd.
  • Genten Therapeutics, Inc.
  • GenVec, Inc.
  • Global Bioscience Company
  • GT Biologics Limited
  • Hartlab LLC
  • Harvest Capital Strategies, LLC
  • HealthMine, Inc
  • IBBL
  • iCarbonX
  • Igen Biotech Group
  • ImmuneBiotech AB
  • Immuron, Ltd.
  • INC Research
  • Intrexon Actobiotics N.V.
  • Intrexon Energy Partners II, LLC
  • Janssen Biotech
  • Kallyope
  • Leading Biosciences
  • LNC Therapeutics
  • Lundbeckfond Ventures
  • MaaT Pharma SA
  • MatriSys Bioscience
  • Microbiome Therapeutics, LLC
  • Microbiomics Limited
  • Mirna Therapeutics
  • Nitrocell
  • NIZO
  • Nubiyota
  • NuMe Health LLC
  • Okanagan Specialty Fruits Inc.
  • Omnes Capital
  • OpenBiome
  • OptiBiotix Health plc
  • OrbiMed HealthCare Fund Management
  • Osel, Inc.
  • OvaXon, LLC
  • Oxitec
  • Symbiotix Biotherapies
  • Synlogic, Inc.
  • Synthetic Biologics, Inc.
  • Synthetic Genomics, Inc.
  • TargEDys
  • Tech Coast Angels (TCA)
  • The Microbiota Company Limited
  • Trans Ova Genetics LC
  • Tucana Health Limited
  • Vedanta Biosciences Inc.
  • Veristat
  • Vertex Pharmaceuticals Inc.
  • Whole Biome
  • Xycrobe Therapeutics

List of Organizations Mentioned in the Report:

  • Alimentary Pharmabiotic Centre
  • APC Microbiome Institute
  • Central Drugs Standard Control Organisation (CDSCO)
  • French National Institute for Agricultural Research
  • Hadasit Medical Research Services & Development Ltd
  • Hadassah Medical Center
  • Health Canada
  • Institut National de la Recherche Agronomique
  • John Theurer Cancer Center of Hackensack Meridian Health
  • King's College London
  • La Trobe University
  • Lawrence Berkeley National Laboratory
  • Leiden University Medical Center
  • Mayo clinic
  • Medical University of Graz
  • Medicines and Healthcare products Regulatory Agency (MHRA)
  • Medicines Control Council (MCC)
  • Memorial Sloan Kettering Cancer Center
  • Microbiome Institute at University College Cork
  • Ministry of Health, Labour and Welfare (MHLW)
  • Monash University
  • Murdoch Children Research Institute
  • National Institute of Allergy and Infectious Diseases
  • NYU Langone Health
  • Orange Country Research Center
  • Pan American Health Organization (PAHO)
  • Roswell Park Comprehensive Cancer Center
  • Ruprecht-Karls-University Heidelberg
  • Saudi Food and Drug Authority (SFDA)
  • St. Joseph's Hamilton
  • Stanford Cancer Institute
  • The Endocrine Society
  • The Parker Institute for Cancer Immunotherapy
  • Therapeutic Goods Administration (TGA)
  • University of British Columbia
  • University of California
  • University of Melbourne
  • University of Minnesota
  • University of Nebraska
  • University of Pennsylvania
  • University of South Alabama (USA) Mitchell Cancer Institut
  • University of Texas at Austin
  • University of Texas MD Anderson Cancer Center
  • University of Tokyo
  • USA Mitchell Cancer Center
  • World Health Organization (WHO)
  • World Intellectual Property Organization WIPO
  • World Trade Organization (WTO)